CXCL5 administration dampens inflammation and improves survival in murine lupus via myeloid and neutrophil pathways.

Xiubo Fan Chin Teck NgDianyang GuoFrances LimJia Chi TanAnnie LawLim Hee GohZhi Yong PoonAlice CheungSay Li KongMichelle TanShang LiAlwin LohAnne JamesTony LimJinmiao ChenJulian ThumbooWilliam HwangAndrea Hsiu Ling Low

Published in: Arthritis & rheumatology (Hoboken, N.J.) (2022)

Taken together, CXCL5 administration may represent a novel myeloid/neutrophil-targeting therapy for SLE.

Keyphrases

systemic lupus erythematosus
disease activity
dendritic cells
bone marrow
acute myeloid leukemia
oxidative stress
rheumatoid arthritis
cancer therapy
free survival
drug delivery